Oryzon adquireix la biofarmacèutica Crystax Notícies

, a biotech company specialising in new biomarkers and therapeutic targets in oncology and neurodegenerative diseases, –with headquarters at the Barcelona Science Park (PCB)– has bought , a company also located at PCB that is dedicated to developing new therapeutic molecules for cancer. This acquisition will be carried out by means of a capital extension in Oryzon underwritten by Crystax shareholders, who will be using their shares and in so doing will also acquire 5.7/ of the capital of the purchasing biotech company.